Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug DT402 aims to ease social struggles in adults with autism

NCT ID NCT07303907

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 16 times

Summary

This study tests an experimental drug called DT402 in 20 adults with autism spectrum disorder. The goal is to see if it can reduce the severity of symptoms like trouble with socializing and communicating. Participants will take the drug and report how they feel using simple rating scales. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Spectrum Neuroscience and Treatment Institute

    RECRUITING

    New York, New York, 10021, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.